Peptide for balancing insulin resistance

I completely understand your situation. Midlife hormonal fluctuation creates a uniquely difficult metabolic environment. Shifting sex hormones directly impair insulin signaling, independent of diet and exercise. This explains why abdominal weight gain gradually appears after you stop Retatrutide, even with consistent healthy lifestyle habits. It is not a problem with your routine; changing hormone levels shift your baseline insulin sensitivity.

Beyond GLP‑1 peptides, multiple research compounds target insulin resistance through different mechanisms.

CJC‑1295 (without DAC) improves growth hormone pulsatility, supports glucose homeostasis and reduces visceral fat accumulation triggered by hormonal insulin resistance.

AOD9604 regulates fat metabolism pathways and boosts insulin sensitivity without powerful appetite suppression, which works well if weight loss is not your main objective.

BPC‑157 is also worth considering. Chronic low-grade inflammation is a key driver of insulin resistance in midlife, and its anti-inflammatory properties can improve metabolic function indirectly.

An important point: there is no one-size-fits-all option. At 47, your hormone baseline is continuously shifting. Any peptide regimen should be introduced slowly. It is sensible to monitor fasting glucose, insulin levels and subjective physical feelings over several weeks. No research peptide can fully replicate the stabilizing metabolic effect of GLP‑1 agonists, but they can provide alternative support during your transition off Retatrutide.